Cargando…
Discovery and Development of Toll-Like Receptor 4 (TLR4) Antagonists: A New Paradigm for Treating Sepsis and Other Diseases
Sepsis remains the most common cause of death in intensive care units in the USA, with a current estimate of at least 750,000 cases per year, and 215,000 deaths annually. Despite extensive research still we do not quite understand the cellular and molecular mechanisms that are involved in triggering...
Autores principales: | Leon, Carlos G., Tory, Rita, Jia, Jessica, Sivak, Olena, Wasan, Kishor M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2469272/ https://www.ncbi.nlm.nih.gov/pubmed/18493843 http://dx.doi.org/10.1007/s11095-008-9571-x |
Ejemplares similares
-
Toll-like receptor 4 (TLR4) antagonists as potential therapeutics for intestinal inflammation
por: Tam, Janine S. Y., et al.
Publicado: (2021) -
TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis
por: Kuzmich, Nikolay N., et al.
Publicado: (2017) -
Association of Toll-like receptors 4 (TLR-4) gene expression and polymorphisms in patients with severe asthma
por: Shukur, Wasan, et al.
Publicado: (2021) -
Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis
por: Ibrahim, Fady, et al.
Publicado: (2013) -
Discovery and Validation of a New Class of Small Molecule Toll-Like Receptor 4 (TLR4) Inhibitors
por: Neal, Matthew D., et al.
Publicado: (2013)